MedWire News: When added to dual anti-platelet therapy (DAT), the orally administered direct thrombin inhibitor (DTI), dabigatran etexilate, results in a “low and acceptable bleeding rate†compared with
placebo in patients who have suffered an acute ...
[MedWire News - 11/19/2009]